ISB 2001
Alternative Names: ABBV-2001; ISB-2001; TREAT™ trispecific antibody - Ichnos SciencesLatest Information Update: 22 Sep 2026
At a glance
- Originator Ichnos Sciences
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Yes - Multiple myeloma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 22 Sep 2026 ISB 2001 is still in phase-I trials for Multiple-myeloma (Second-line therapy or greater) in Australia (NCT05862012)
- 28 Aug 2026 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in Australia (Parenteral, Injection)
- 28 Dec 2025 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)